Repositioning drugs to fight COVID-19

“French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting,” the researchers wrote in an abstract. “Depending on their clinical presentation, azithromycin was added to the treatment.”

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

“Hydroxychloroquine and chloroquine have been recommended by Chinese and South Korean health authorities for the treatment COVID-19.[31] In vitro studies in cell cultures demonstrated that hydroxychloroquine was more potent than chloroquine against SARS-CoV-2.[32][33]

“On March 17 after testing in several hospitals around Italy the Italian Pharmaceutical Agency has included hydroxychloroquine in the list of drugs with positive preliminary results for treatment of coronavirus disease 2019.[38]”

Hydroxychloroquine is an inexpensive drug  that must be prescribed by medical professionals.  Hydroxychloroquine (HCQ), sold under the brand name Plaquenil among others, is a medication used for the prevention and treatment of certain types of malaria. Specifically it is used for chloroquine sensitive malaria. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda.  Use only under a doctors care and instructions.  There can be serious side effects.


References above thanks to Wikipedia

  1. Physicians work out treatment guidelines for coronavirus”. Korea Biomedical Review. 13 February 2020. Retrieved 18 March 2020.


  1. Yao, Xueting; Ye, Fei; Zhang, Miao; Cui, Cheng; Huang, Baoying; Niu, Peihua; Liu, Xu; Zhao, Li; Dong, Erdan; Song, Chunli; Zhan, Siyan (9 March 2020). “In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)”. Clinical Infectious Diseases. doi:10.1093/cid/ciaa237. ISSN 1537-6591. PMID 32150618.


  1. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine. Int J Antimicrob Agents. 2020 Mar 16:105945. doi:10.1016/j.ijantimicag.2020.105945 PMID 32194152 (edited)

38  “Azioni intraprese per favorire la ricerca e l’accesso ai nuovi farmaci per il trattamento del COVID-19”. Italian Medicines Agency (AIFA) (in Italian). 17 March 2020. Retrieved 18 March 2020.


About budbromley

Bud is a retired life sciences executive. Bud's entrepreneurial leadership exceeded three decades. He was the senior business development, marketing and sales executive at four public corporations, each company a supplier of analytical and life sciences instrumentation, software, consumables and service. Prior to those positions, his 19 year career in Hewlett-Packard Company's Analytical Products Group included worldwide sales and marketing responsibility for Bioscience Products, Global Accounts and the International Olympic Committee, as well as international management assignments based in Japan and Latin America. Bud has visited and worked in more than 65 countries and lived and worked in 3 countries.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.